This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Knable, M. B. Articles by Weinberger, D. R. Search for Related Content PubMed PubMed Citation Articles by Knable, M. B. Articles by Weinberger, D. R. Social Bookmarking                         What's this?

Dopamine, the prefrontal cortex and schizophrenia

National Institute of Mental Health, Intramural Research Program, Clinical Brain Disorders Branch, 2700 Martin Luther King Jr, Avenue SE, Washington, DC 20032, USA

Daniel R. Weinberger

National Institute of Mental Health, Intramural Research Program, Clinical Brain Disorders Branch, 2700 Martin Luther King Jr, Avenue SE, Washington, DC 20032, USA

Dysfunction of the prefrontal cortex (PFC) in schizophrenia has been suspected based on observations from clinical, neuropsychological and neuroimaging studies. Since the PFC receives a dense dopaminergic innervation, abnormalities of the mesocortical dopamine system have been proposed to contribute to the pathophysiology of schizophrenia. In this review, aspects of the anatomy, physiology and pharmacology of the mesencephalic-frontal cortical dopamine system as they may relate to schizophrenia are described, and evidence for altered dopaminergic neurotransmission in the frontal cortex of schizophrenic patients is presented.

Key Words: antipsychotic drugs • dopamine • dopamine receptors • prefrontal cortex • schizophrenia

Journal of Psychopharmacology, Vol. 11, No. 2, 123-131 (1997)
DOI: 10.1177/026988119701100205


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. W. Buchanan, R. Freedman, D. C. Javitt, A. Abi-Dargham, and J. A. Lieberman Recent Advances in the Development of Novel Pharmacological Agents for the Treatment of Cognitive Impairments in Schizophrenia Schizophr Bull, September 1, 2007; 33(5): 1120 - 1130. [Abstract] [Full Text] [PDF]

				K. Harris and H. S. Singer Tic Disorders: Neural Circuits, Neurochemistry, and Neuroimmunology J Child Neurol, August 1, 2006; 21(8): 678 - 689. [Abstract] [PDF]

				L. Zhang, Y. Liu, and X. Chen Carbachol induces burst firing of dopamine cells in the ventral tegmental area by promoting calcium entry through L-type channels in the rat J. Physiol., October 15, 2005; 568(2): 469 - 481. [Abstract] [Full Text] [PDF]

				H. Homayoun, M. E. Jackson, and B. Moghaddam Activation of Metabotropic Glutamate 2/3 Receptors Reverses the Effects of NMDA Receptor Hypofunction on Prefrontal Cortex Unit Activity in Awake Rats J Neurophysiol, April 1, 2005; 93(4): 1989 - 2001. [Abstract] [Full Text] [PDF]

				A. Abi-Dargham and H. Moore Prefrontal DA Transmission at D1 Receptors and the Pathology of Schizophrenia Neuroscientist, October 1, 2003; 9(5): 404 - 416. [Abstract] [PDF]

				R. A. Bantick, J. F. W. Deakin, and P. M. Grasby The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J Psychopharmacol, January 1, 2001; 15(1): 37 - 46. [Abstract] [PDF]

				J. D. Jentsch, J. R. Taylor, and R. H. Roth Phencyclidine Model of Frontal Cortical Dysfunction in Nonhuman Primates Neuroscientist, August 1, 2000; 6(4): 263 - 270. [Abstract] [PDF]